Zhejiang Jianfeng Pharmaceutical Co., Ltd.

This product can inhibit the occurrence of cachexia in tumor-bearing mice.

(1) It selectively inhibits the classical guanine synthesis pathway of lymphocytes and has no toxic effects on non-lymphocytes and/or organs; (2) It directly inhibits B cell proliferation, while cyclosporine has no effect on inhibiting antibody formation; (3) It effectively reduces the activity of adhesion molecules and inhibits the proliferation of vascular smooth muscle cells, which can prevent and treat vascular rejection reactions and reduce the occurrence of chronic rejection reactions.

It is a third-generation cephalosporin that kills bacteria by inhibiting the biosynthesis of the cell wall of sensitive bacteria.

It has an irreversible inhibitory effect on most important β-lactamases produced by β-lactam antibiotic-resistant strains, and can protect β-lactam antibiotics from hydrolysis and destruction by β-lactamases of resistant bacteria; it can combine with certain penicillin-binding proteins to enhance the sensitivity of this compound preparation

The second generation cephalosporin antibiotics have similar or slightly worse antibacterial activity against Gram-positive cocci than the first generation cephalosporins, but are quite stable against beta-lactamase produced by Staphylococci and Gram-negative bacilli. Methicillin-resistant Staphylococci, Enterococci and Listeria are resistant, and other positive cocci (including anaerobic cocci) are sensitive to this product. The antibacterial activity against Staphylococcus aureus is worse than that of cefazolin, and 1-2 mg/L can inhibit all Staphylococcus aureus that are sensitive and resistant to penicillin, respectively. It has strong antibacterial activity against Haemophilus influenzae, and Escherichia coli, Proteus mirabilis, etc. may be sensitive to this product; indole-positive Proteus, Citrobacter and Acinetobacter are poorly sensitive to this product, Serratia is mostly resistant, Pseudomonas aeruginosa, Campylobacter and Bacteroides fragilis are resistant to this product. Its mechanism of action is to bind to penicillin-binding proteins (PBPs) on the bacterial cell membrane, acylate the transpeptidase, inhibit the synthesis of the bacterial septum and cell wall, affect the cross-linking of the cell wall mucopeptide components, inhibit cell division and growth, elongate the bacterial morphology, and finally dissolve and die.

This product is a second-generation cephalosporin antibiotic. Its antibacterial activity against Gram-positive cocci is similar to or slightly worse than that of the first-generation cephalosporins, but it is quite stable against beta-lactamase produced by Staphylococci and Gram-negative bacilli. Methicillin-resistant Staphylococci, Enterococci and Listeria are resistant, and other positive cocci (including anaerobic cocci) are sensitive to this product. Its antibacterial activity against Staphylococcus aureus is worse than that of cefazolin. 1-2 mg/L can inhibit all Staphylococcus aureus that are sensitive and resistant to penicillin, respectively. It has strong antibacterial activity against Haemophilus influenzae, and Escherichia coli, Proteus mirabilis, etc. may be sensitive to this product; indole-positive Proteus, Citrobacter and Acinetobacter have poor sensitivity to this product, most Serratia are resistant, and Pseudomonas aeruginosa, Campylobacter and Bacteroides fragilis are resistant to this product. Its mechanism of action is to bind to penicillin-binding proteins (PBPs) on the bacterial cell membrane, acylate the transpeptidase, inhibit the synthesis of the bacterial septum and cell wall, affect the cross-linking of the cell wall mucopeptide components, inhibit cell division and growth, elongate the bacterial morphology, and finally dissolve and die.